期刊
CLINICAL CANCER RESEARCH
卷 15, 期 19, 页码 5945-5946出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-09-1650
关键词
-
类别
资金
- NATIONAL CANCER INSTITUTE [P01CA109552, P50CA095060, P01CA017094] Funding Source: NIH RePORTER
- NCI NIH HHS [CA095060, P50 CA095060, CA0179094, P01 CA109552-040002, P01 CA017094-290031, P01 CA109552, CA109552, P01 CA017094, P50 CA095060-080003] Funding Source: Medline
The hypoxia-inducible transcription factor (HIF)-1 alpha inhibitor KC7F2 described in this issue of Clinical Cancer Research is the newest addition to an emerging class of antitumor agents targeting the hypoxia response. Here, we discuss the proposed mechanism of action of KC7F2 and its potential strengths and limitations in comparison with other promising HIF-1 alpha inhibitors. (Clin Cancer Res 2009;15(19):5945-6)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
